ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer https://t.co/68EHCRlouD
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
@ItchinsMalinda - a must read!
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
@OncoAlert
RT @JTOonline: JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non…
JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer." #LCSM #LungCancer #ALK #NSCLC https://t.co/ObFRYQqMYU
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
RT @mlazqui: ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cance…
ALK Resistance Mutations and Efficacy of #Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/HMnm9n9UNs
RT @drtclay: My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently disc…
RT @drtclay: My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently disc…
RT @drtclay: My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently disc…
RT @drtclay: My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently disc…
RT @drtclay: My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently disc…
My take on this paper is that tumour/plasma genotyping in ALK post 2nd gen / pre lortainib is useful but not sufficiently discriminatory... #lcsm #ALK https://t.co/Z4XRjLFzSe
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
Impressive results with difficult to treat acquired resistance mutation
RT @bensolomon1: Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
Activity of Lorlatinib in setting of ALK G1202R mutation https://t.co/tiYC49W0cP @JCO_ASCO https://t.co/Aa4qQ8wBzn
RT @MSPneu: ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer…
Lorlatinib shows efficacy in patients with pretreated ALK+ NSCLC and ALK resistance mutations. ORR in this setting is 69% #lcsm #OncoAlert https://t.co/b4RV6LN4TL
RT @JackWestMD: Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlat…
RT @JackWestMD: Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlat…
Good point but I do wonder whether in the non mut pts could have a logic to consider chemo instead of TKI.
La tipizzazione genetica del tumore per le mutazioni ALK, dopo fallimento di un TKI di seconda generazione può identificare pazienti che hanno maggiori probabilità di trarre beneficio clinico da Lorlatinib. https://t.co/aiX5ZqgzyY
RT @JackWestMD: Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlat…
RT @JackWestMD: Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlat…
RT @JackWestMD: Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlat…
RT @MSPneu: ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer…
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/2RmzXRrKhn
RT @JCO_ASCO: ALK resistance mutations and efficacy of lorlatinib in advanced AKL-positive NSCLC https://t.co/pHRXLk8i9r #lcsm
RT @n8pennell: Another great study but not sure this is compelling reason to biopsy outside trial, still 30% ORR w/o muts=> ALK Resistance…
RT @NatRevClinOncol: in study published in J Clin Oncol, ALK resistance mutations seem to indicate a response to lorlatinib in later-line s…
Agree on both counts. Interesting info on biology, but no reason to change management if every result still suggests lorlatinib is best next option. Another notable point is lack of great concordance of plasma w/tissue testing, & sensitivity w/plasma
RT @JCO_ASCO: ALK resistance mutations and efficacy of lorlatinib in advanced AKL-positive NSCLC https://t.co/pHRXLk8i9r #lcsm
RT @n8pennell: Another great study but not sure this is compelling reason to biopsy outside trial, still 30% ORR w/o muts=> ALK Resistance…
RT @NatRevClinOncol: in study published in J Clin Oncol, ALK resistance mutations seem to indicate a response to lorlatinib in later-line s…
RT @JCO_ASCO: ALK resistance mutations and efficacy of lorlatinib in advanced AKL-positive NSCLC https://t.co/pHRXLk8i9r #lcsm
RT @m0370: JCOも筆の誤り。 https://t.co/Ac8x7NyuKa
JCOも筆の誤り。
RT @JCO_ASCO: ALK resistance mutations and efficacy of lorlatinib in advanced AKL-positive NSCLC https://t.co/pHRXLk8i9r #lcsm
ALK resistance mutations and efficacy of lorlatinib in advanced AKL-positive NSCLC https://t.co/pHRXLk8i9r #lcsm
Another great study but not sure this is compelling reason to biopsy outside trial, still 30% ORR w/o muts=> ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced ALK+ NSCLC #LCSM https://t.co/dSZGAmK8Fl
RT @GlopesMd: Molecular determinants of lorlatinib in #LCSM @oncoalert #oncoalert https://t.co/xhjLY5olHi
RT @NatRevClinOncol: in study published in J Clin Oncol, ALK resistance mutations seem to indicate a response to lorlatinib in later-line s…
RT @NatRevClinOncol: in study published in J Clin Oncol, ALK resistance mutations seem to indicate a response to lorlatinib in later-line s…
#ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer https://t.co/c7aCfWulXN @ASCO #LCSM @ALKLungCancer @UKALK1
RT @GlopesMd: Molecular determinants of lorlatinib in #LCSM @oncoalert #oncoalert https://t.co/xhjLY5olHi
Molecular determinants of lorlatinib in #LCSM @oncoalert #oncoalert https://t.co/xhjLY5olHi
in study published in J Clin Oncol, ALK resistance mutations seem to indicate a response to lorlatinib in later-line settings https://t.co/9izRE85Hr1 #lcsm
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. - PubMed - NCBI https://t.co/ZkIpJvugEq #hvhebron #onco @JCO_ASCO